Literature DB >> 27605780

The role of Montanide ISA 70 as an adjuvant in immune responses against Leishmania major induced by thiol-specific antioxidant-based protein vaccine.

Narges Khabazzadeh Tehrani1, Mehdi Mahdavi2, Fatemeh Maleki3, Somayeh Zarrati1, Fatemeh Tabatabaie4.   

Abstract

Leishmaniasis is a parasitic disease caused by several species of the genus Leishmania. Montanide ISA 70 is an adjuvant composed of a natural metabolizable oil and a very refined emulsifier from the manide monooleate family. The TSA (thiol-specific antioxidant) is a important antigen of Leishmania major. The purpose of this work was protein-vaccine efficacy as an protection and excellent candidate in the presence Montanide. The expression of recombinant protein was confirmed with SDS (sodium dodecyl sulfate) page and Western bloting. 48 BALB/c mice were divided into four groups (TSA/Freund,TSA/Alum + BCG, TSA/Montanide and PBS groups) and immunized with 20 μg of vaccine subcutaneously three times intervals on days 0, 14 and 28. The mice were challenged with parasite 21 days after final immunization. The lymphocyte proliferation was evaluated with Brdu method. Cytokines and also total antibody and subclasses were evaluated with ELISA method. The vaccine formulated with the recombinant TSA protein with Montanide induced lymphocytes proliferation cytokines and total antibody and subclasses as compared with the control group.

Entities:  

Keywords:  BCG; IFN-γ; Leishmaniasis; Montanide; TSA; Vaccine

Year:  2014        PMID: 27605780      PMCID: PMC4996187          DOI: 10.1007/s12639-014-0574-8

Source DB:  PubMed          Journal:  J Parasit Dis        ISSN: 0971-7196


  34 in total

Review 1.  Adjuvant formulations and delivery systems for DNA vaccines.

Authors:  Shin Sasaki; Fumihiko Takeshita; Ke Qin Xin; Norihisa Ishii; Kenji Okuda
Journal:  Methods       Date:  2003-11       Impact factor: 3.608

2.  Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines.

Authors:  Jerome Aucouturier; L Dupuis; S Deville; S Ascarateil; V Ganne
Journal:  Expert Rev Vaccines       Date:  2002-06       Impact factor: 5.217

Review 3.  What about Th1/Th2 in cutaneous leishmaniasis vaccine discovery?

Authors:  A Campos-Neto
Journal:  Braz J Med Biol Res       Date:  2005-07-04       Impact factor: 2.590

4.  Expression cloning of a protective Leishmania antigen.

Authors:  E Mougneau; F Altare; A E Wakil; S Zheng; T Coppola; Z E Wang; R Waldmann; R M Locksley; N Glaichenhaus
Journal:  Science       Date:  1995-04-28       Impact factor: 47.728

5.  Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes.

Authors:  H Z Chae; K Robison; L B Poole; G Church; G Storz; S G Rhee
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

6.  Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice.

Authors:  A Campos-Neto; J R Webb; K Greeson; R N Coler; Y A W Skeiky; S G Reed
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

Review 7.  Immunology of cutaneous leishmaniasis: the role of mast cells, phagocytes and dendritic cells for protective immunity.

Authors:  Esther Von Stebut
Journal:  Eur J Dermatol       Date:  2007-03-02       Impact factor: 3.328

8.  Protection against cutaneous leishmaniasis in outbred vervet monkeys using a recombinant histone H1 antigen.

Authors:  Slavica Masina; Michael M Gicheru; Stéphane O Demotz; Nicolas J Fasel
Journal:  J Infect Dis       Date:  2003-10-01       Impact factor: 5.226

9.  A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major.

Authors:  Sami Ben Hadj Ahmed; Chokri Bahloul; Cyrine Robbana; Souhir Askri; Koussay Dellagi
Journal:  Vaccine       Date:  2004-04-16       Impact factor: 3.641

10.  A review of adjuvants for Leishmania vaccine candidates.

Authors:  Joshua M Mutiso; John C Macharia; Michael M Gicheru
Journal:  J Biomed Res       Date:  2010-01
View more
  4 in total

1.  Protective Effectiveness of an Immunization Protocol Against the Toxic Effects of Loxosceles intermedia Venom in Rabbits.

Authors:  Ana Luísa Soares de Miranda; Sabrina de Almeida Lima; Ana Flávia Machado Botelho; Marco Túlio Gomes Campos; Camila Eckstein; João Carlos Minozzo; Carlos Delfin Chávez-Olórtegui; Benito Soto-Blanco
Journal:  Front Vet Sci       Date:  2022-05-31

2.  Inactivated alpha toxin from Clostridium novyi type B in nano-emulsion protect partially protects Swiss mice from lethal alpha toxin challenge.

Authors:  Mellanie Karoline C Felix; Tullio T Deusdará; Lucas Samuel S Santos; Raimundo Wagner S Aguiar; Roberto Franco T Corrêa; Igor V Brandi; Eliane M Sobrinho; Bergmann M Ribeiro; Luis André M Mariúba; Paulo A Nogueira; Kattyanne S Costa; Kelvinson F Viana; Alex Sander R Cangussu
Journal:  Sci Rep       Date:  2019-10-01       Impact factor: 4.379

3.  A novel bivalent Pasteurellosis-RHD vaccine candidate adjuvanted with Montanide ISA70 protects rabbits from lethal challenge.

Authors:  Jakeen K El-Jakee; Ihab M Moussa; Mai S Omran; Basem M Ahmed; Mahmoud A Elgamal; Hassan A Hemeg; Ayman S Mubarak; Khalid S Al-Maary; Saleh A Kabli; Sherif A Marouf; Jwaher Haji Alhaaji
Journal:  Saudi J Biol Sci       Date:  2020-01-08       Impact factor: 4.219

Review 4.  An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery.

Authors:  Kailash C Petkar; Suyash M Patil; Sandip S Chavhan; Kan Kaneko; Krutika K Sawant; Nitesh K Kunda; Imran Y Saleem
Journal:  Pharmaceutics       Date:  2021-03-27       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.